Can GLP-1 Medications Cause Vision Loss? The New FDA Warning Explained
From Peptides Explained · 10:28
Show by John Garrett
True-Sciences.com use code PEP30 for 30% off your first order through Nov 22, 2026. After that it goes back to 20% off with PEP20 **Excuse the hoarseness in my voice...I am fighting off a cold that is going around my family...so far, I've only gotten hoarse. The FDA is requiring new warnings for GLP-1 medications after reviewing a possible association with non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden and sometimes permanent vision loss. John Garrett explains what NAION is, how to interpret the FDA's trial data, what European regulators concluded about semaglutide, and why the evidence should be taken seriously without exaggerating individual risk. Sudden vision loss warrants emergency evaluation. Sources and further reading: FDA https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential ; EMA https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy
More episodes of Peptides Explained
More episodes
- Kisspeptin: Can It Restart Natural Testosterone Production?
- The Secretome Explained: Could Cellular Signaling Transform Medicine?
- Monkeys Got Shredded On Peptides?!!
- Where Do Peptides Fit in Pain and Recovery? | Dr. Hany Demian
- BPC-157 Update: HHS Policy, Human Evidence & WADA Status
- Beyond Stem Cells: Secretomes, Cellular Repair & Longevity | Sanjiv Lal
- CJC-1295 Deep Dive: What the Human Evidence Actually Shows
- The Silent Killer in Your Kitchen? Seed Oils, Inflammation & What to Cook With Instead with Cherie Calbom
- Retatrutide: Is It Time to Panic? Lilly's Lawsuits, the Science, and What Happens Next
- Can Peptides Protect the Brain From Vascular Damage?
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.